Track topics on Twitter Track topics that are important to you
Shares of Geron Corp. were down 5.7% to $2.50 in premarket trading on Tuesday, Aug. 1, after the Menlo Park, Calif.-based firm on Monday gave updates on the development plans for ongoing clinical studies of telomerase inhibitor imetelstat being conducted by Johnson & Johnson's Janssen Research & Development LLC. Geron said that for the IMerge study, which focuses on lower risk myelodysplastic syndromes, part 1 will be broadened to "enroll additional patients in a refined MDS population to confirm the clinical benefit and safety observed from current results." As for the IMbark trial, which focuses on relapsed or refractory myelofibrosis, the study is unchanged.NEXT ARTICLE
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...